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Abstracts 461
ple (n  20,088) of adult residents from the Baltimore, MD
and Chicago, IL areas was contacted by phone, of whom
7,691 met occupation eligibility criteria. Respondents were
randomized to one of the six interviews at the time of con-
tact. Interviews were compared on the basis of estimates of
work loss and variation in estimates of work loss associated
with recall period and version.
RESULTS: Interviews varied in average length from 9.2
minutes (V3) to 15.1 minutes (V1). The participation rate
(66%) did not vary with the version. Estimates of work
loss varied with recall period and version. The mean total
hours/week of lost productive work time was lower for
interviews using a four-week compared to a one-week re-
call period. V3 of the interviews was the most discrim-
inating for illness-related work-loss estimates. For ex-
ample, individuals with allergic rhinitis (AR) reported
significantly more lost productive time at work due to
not feeling well compared to controls and a stronger rela-
tion between severity of AR and work loss.
CONCLUSION: Variation in relatively short recall peri-
ods influences estimates of work loss. Interview version 3
required the least time to administer and was the most
discriminating in terms of work-loss estimates by illness
status and illness severity.
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OBJECTIVE: To collect information on knowledge of
asthma by patients (pts), on its management and outcomes.
METHODS: multi-center, cross-sectional survey. Patients
(pts) were administered a questionnaire derived from the
one used in the survey “Asthma Insights & Reality in Eu-
rope” (A.I.R.E.). The questionnaire was adapted for ad-
ministration during a visit, instead of by phone as done
during A.I.R.E.
RESULTS: During the second half of 2000, 105 pneu-
mologists administered the questionnaire to 1017 asth-
matic pts (972 fully evaluable). Urban population repre-
sented 53% of the sample, males were 44%, mean age
was 44 years, and 35% suffered from seasonal asthma.
Relatives suffering from asthma were reported by 39% of
pts. Most pts (80%) believed that the number of Italian
asthmatics had increased during the last decade. Those
who rated their health status as at least good were 60%.
Fifty three percent thought that their asthma was better
today than 10 years ago. During the last 12 months, se-
vere symptoms were reported by 44% of pts, 11% of pts
spent at least one night in hospital, 16% reported access-
ing an emergency department, and 34% had an unsched-
uled visit. During the last four weeks, asthma was re-
ported as very good/good by 53%. In the same time,
72% of pts reported symptoms of various severity, and
40% of pts had night awakening. The peak flow meter
was known by 54% of pts. Thirty two percent of pts
owned one, but more than 50% of pts did not use it or
used it only when symptoms appeared. Half of pts under-
went lung functionality tests during the last 12 months.
CONCLUSION: Our data suggest that asthma manage-
ment does not usually fit the GINA guidelines. Health
status reported by pts does not always correspond with
symptom severity assessed by doctors. The hospitaliza-
tion rate and unscheduled visits due to asthma seem to be
higher than expected.
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OBJECTIVES: To determine the cost-effectiveness of ba-
sic monotherapy for bronchial asthma in children with
nedocromil sodium with or without specific immunotro-
pic therapy (SIT).
METHODS: Criteria for effectiveness were the number
of asymptomatic days per year and a complex estimation
by A. Zemskov (1997) which includes dynamics, clinical
and immunochemical markers of allergic inflammation.
Direct and indirect costs were calculated using data from
patient diaries with daily recording of medication and
medical care. We observed 100 children with moderately
severe asthma. The first group received monotherapy
with nedocromil sodium. The second group received
nedocromil sodium with SIT domestic allergens.
RESULTS: The study revealed that use of nedocromil so-
dium in 84.0 
 4.23% of the children provided 327.24 

1.04 asymptomatic days per year. The cost of one asymp-
tomatic day was 15.44 
 0.26 rubles. The use of SIT in
the first year of treatment improved the control of
asthma, and the number of asymptomatic days per year
was 333,8 
 1,01. The cost of one asymptomatic day in
this group is 12,04 
 0,28 rubles. Incremental cost-effec-
tiveness ratio in group with SIT was 171,71. This com-
plex analysis of the index with determination of clinico-
immunological effectiveness was 944,41.
CONCLUSIONS: Our investigation showed that SIT in
children with moderately severe asthma improved the ef-
fectiveness of basic therapy and reduced expenditures.
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